Building access to the Regenstrief Institute is restricted at least through September 13, 2020. More on our coronavirus precautions.
See our coronavirus precautions.
Patient on life support in ICU

A new study shows that critically ill patients are not benefitting from antipsychotic medications that doctors have been using to treat delirium in patients in intensive care units. The evidence suggests doctors may need to re-examine the practice. Regenstrief investigator Babar Khan, M.D., was a co-author on the study.

Each year, more than seven million hospitalized patients in the United States develop delirium. The acute brain failure results in confusion and long-term memory problems.

The large study, MIND-USA (Modifying the INcidence of Delirium), sought to answer whether typical and atypical antipsychotics — haloperidol or ziprasidone — affected delirium, survival, length of stay or safety in ICU patients. Researchers screened nearly 21,000 patients at 16 U.S. medical centers. Of the 1,183 patients on mechanical ventilation or in shock, 566 became delirious and were randomized into groups receiving either intravenous haloperidol, ziprasidone or placebo (saline). Results showed that patients who received the drugs did not experience any improvements whatsoever in delirium, coma, length of stay or survival.

Study authors say the medicines are bringing risk and cost without benefit, based on the outcomes measured in this study. Doctors have been prescribing the drugs for 40 years.

Dr. Khan, who worked on this study, has conducted extensive studies on treating and preventing delirium. He led a project at Regenstrief that developed and validated the Confusion Assessment Method for the Intensive Care Unit 7. It’s an easy-to-use method to determine the severity of delirium.

The MIND-USA study was published in the New England Journal of Medicine. It was funded by the National Institute on Aging.

Related News

Jul 07, 2020 • News
New healthcare codes released, including terms used internationally to track coronavirus
System provides common language for seamless exchange of health data in 179 countries LOINC®, created and maintained by the Regenstrief Institute, is amplifying its global work to help track the coronavirus by releasing new standardized codes for healthcare systems’ laboratory tests, clinical observations and other data. Health systems often have their own format for recording…
Continue Reading >
Jul 06, 2020 • News
During COVID-19 disruption, Regenstrief and CTSI offer free continuing education classes
60 from Notre Dame, IU, Purdue, Duke, Ohio State, Oregon participate Amid the work disruptions from COVID-19, Regenstrief Institute and Indiana Clinical and Translational Sciences Institute (CTSI) are providing free opportunities for research professionals to continue their education. After a successful launch to Regenstrief and Indiana University employees, the institute made classes available to Indiana…
Continue Reading >